SCM
TVTX icon

Superstring Capital Management’s Travere Therapeutics TVTX Stock Holding History

Superstring Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.05M Buy
102,754
+64,732
+170% +$1.94M 2.18% 19
2025
Q4 		$1.45M Sell
38,022
-15,605
-29% -$507K 0.78% 31
2025
Q3 		$1.28M Sell
53,627
-222,847
-81% -$4.19M 1.26% 28
2025
Q2 		$4.09M Buy
276,474
+38,987
+16% +$646K 4.84% 10
2025
Q1 		$4.26M Buy
+237,487
New +$4.82M 5.06% 9

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Superstring Capital Management's TVTX Position: Q1 2026 in Review

Superstring Capital Management increased its Travere Therapeutics (TVTX) stake by 170% in Q1 2026, buying an estimated $1.94M and bringing the position to 102,754 shares worth $3.05M. The position accounts for 2.18% of the portfolio, ranked #19.

Superstring Capital Management first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.26M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Superstring Capital Management held 102,754 shares of Travere Therapeutics worth $3.05M as of Q1 2026.
  • Superstring Capital Management bought 64,732 Travere Therapeutics shares in Q1 2026, an estimated $1.94M.
  • Travere Therapeutics made up 2.18% of Superstring Capital Management's portfolio in Q1 2026, its #19 holding.
  • Superstring Capital Management first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Superstring Capital Management's Travere Therapeutics position peaked at $4.26M in Q1 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.